Search

Your search keyword '"Nademanee, Auayporn"' showing total 855 results
Start Over Author "Nademanee, Auayporn"
855 results on '"Nademanee, Auayporn"'

1. Yttrium-90 anti-CD25 BEAM conditioning for autologous hematopoietic cell transplantation in Peripheral T-cell lymphoma

Author

Zain, Jasmine, Tsai, Ni-Chun, Palmer, Joycelynne, Simpson, Jennifer, Adhikarla, Vikram, Bading, James R., Yazaki, Paul, Smith, Eileen P., Dandapani, Savita, Song, Joo Y., Karras, Nicole A., Herrera, Alex F., Salhotra, Amandeep, Nademanee, Auayporn P., Nakamura, Ryotaro, Smith, D. Lynne, Yamauchi, David, Poku, Erasmus K., Biglang-Awa, V. Eric, Colcher, David, Shively, John E., Wu, Anna M., Forman, Stephen J., Wong, Jeffrey, and Thomas, Sandra

Published
2024
Full Text
View/download PDF

2. Treatment of Allosensitized Patients Receiving Allogeneic Transplantation

Author

Ciurea, Stefan O, Malki, Monzr M Al, Kongtim, Piyanuch, Zou, Jun, Aung, Fleur M, Rondon, Gabriela, Chen, Julianne, Taniguchi, Michiko, Otoukesh, Salman, Nademanee, Auayporn, Forman, Stephen J, Champlin, Richard E, Gendzekhadze, Ketevan, and Cao, Kai

Subjects
Biomedical and Clinical Sciences, Cardiovascular Medicine and Haematology, Clinical Research, Stem Cell Research, Transplantation, Female, HLA Antigens, Hematopoietic Stem Cell Transplantation, Humans, Male, Middle Aged, Rituximab, Tissue Donors, Transplantation, Homologous, Cardiovascular medicine and haematology
Abstract

Donor-specific anti-HLA antibodies (DSAs) are a major cause of engraftment failure in patients receiving haploidentical stem cell transplantation (HaploSCT). Effective treatments are needed for these patients, who often have no other donor options and/or are in need to proceed urgently to transplantation. We studied a multimodality treatment with alternate-day plasma exchange (PE), rituximab, intravenous γ globulin (IVIg) and an irradiated donor buffy coat for patients with DSAs at 2 institutions. Thirty-seven patients with a median age of 51 years were treated with this desensitization protocol. Treatment outcomes were compared with a control group of HaploSCT patients without DSAs (n = 345). The majority of patients in the DSA group were female (83.8% vs 37.1% in controls, P < .001) and received stem cells from a child as the donor (67.6% vs 44.1%, P = .002). Mean DSA level before and after desensitization was 10 198 and 5937 mean fluorescence intensity (MFI), respectively, with mean differences of 4030 MFI. Fourteen of 30 tested patients (46.7%) had C1q positivity, while 8 of 29 tested patients (27.6%) remained positive after desensitization. In multivariable analysis, patients with initial DSA > 20 000 MFI and persistent positive C1q after desensitization had a significantly lower engraftment rate, which resulted in significantly higher non-relapse mortality and worse overall survival (OS) than controls, whereas graft outcome and survival of patients with initial DSA < 20 000 MFI and those with negative C1q after treatment were comparable with controls. In conclusion, treatment with PE, rituximab, IVIg, and donor buffy coat is effective in promoting engraftment in patients with DSAs ≤20 000 MFI.

Published
2021

3. Results of a Phase II Trial of Allogeneic Hematopoietic Stem Cell Transplantation Using 90Y-Ibritumomab Tiuxetan (Zevalin) in Combination With Fludarabine and Melphalan in Patients With High-Risk B-Cell Non-Hodgkin's Lymphoma

Author

Mei, Matthew, Palmer, Joycelynne, Tsai, Nicole Ni-Chun, Simpson, Jennifer, O'Hearn, James, Stein, Anthony, Forman, Stephen, Spielberger, Ricardo, Cai, Ji-Lian, Htut, Myo, Nakamura, Ryotaro, Al Malki, Monzr M., Herrera, Alex, Wong, Jeffrey, and Nademanee, Auayporn

Published
2023
Full Text
View/download PDF

4. Brentuximab vedotin plus nivolumab after autologous haematopoietic stem-cell transplantation for adult patients with high-risk classic Hodgkin lymphoma: a multicentre, phase 2 trial

Author

Herrera, Alex F, Chen, Lu, Nieto, Yago, Holmberg, Leona, Johnston, Patrick, Mei, Matthew, Popplewell, Leslie, Armenian, Saro, Cao, Thai, Farol, Leonardo, Sahebi, Firoozeh, Spielberger, Ricardo, Chen, Robert, Nademanee, Auayporn, Puverel, Sandrine, Nwangwu, Mary, Lee, Peter, Song, Joo, Skarbnik, Alan, Kennedy, Neena, Peters, Lacolle, Rosen, Steven T, Kwak, Larry W, Forman, Stephen J, and Feldman, Tatyana

Published
2023
Full Text
View/download PDF

5. Response-adapted anti-PD-1–based salvage therapy for Hodgkin lymphoma with nivolumab alone or in combination with ICE

Author

Mei, Matthew G., Lee, Hun Ju, Palmer, Joycelynne M., Chen, Robert, Tsai, Ni-Chun, Chen, Lu, McBride, Kathryn, Smith, D. Lynne, Melgar, Ivana, Song, Joo Y., Bonjoc, Kimberley-Jane, Armenian, Saro, Nwangwu, Mary, Lee, Peter P., Zain, Jasmine, Nikolaenko, Liana, Popplewell, Leslie, Nademanee, Auayporn, Chaudhry, Ammar, Rosen, Steven, Kwak, Larry, Forman, Stephen J., and Herrera, Alex F.

Published
2022
Full Text
View/download PDF

6. Anti-CD25 Radioimmunotherapy with BEAM Autologous Hematopoietic Cell Transplantation Conditioning in Hodgkin Lymphoma

Author

Herrera, Alex F., Palmer, Joycelynne, Adhikarla, Vikram, Yamauchi, Dave, Poku, Erasmus K., Bading, James, Yazaki, Paul, Dandapani, Savita, Mei, Matthew, Chen, Robert, Cao, Thai, Karras, Nicole, McTague, Pamela, Nademanee, Auayporn, Popplewell, Leslie, Sahebi, Firoozeh, Shively, John E., Simpson, Jennifer, Smith, D. Lynne, Song, Joo, Spielberger, Ricardo, Tsai, Ni-Chun, Thomas, Sandra H., Forman, Stephen J., Colcher, David, Wu, Anna M., Wong, Jeffrey, and Smith, Eileen

Published
2021
Full Text
View/download PDF

7. Haploidentical Transplantation with Post-Transplantation Cyclophosphamide for High-Risk Acute Lymphoblastic Leukemia.

Author

Srour, Samer, Milton, Denái, Bashey, Asad, Karduss-Urueta, Amado, Al Malki, Monzr, Romee, Rizwan, Solomon, Scott, Nademanee, Auayporn, Brown, Stacey, Slade, Michael, Perez, Rosendo, Rondon, Gabriela, Forman, Stephan, Champlin, Richard, Kebriaei, Partow, and Ciurea, Stefan

Subjects
Acute lymphoblastic leukemia, Haploidentical transplantation, Adolescent, Adult, Allografts, Cyclophosphamide, Disease-Free Survival, Drug Evaluation, Female, Graft vs Host Disease, Hematopoietic Stem Cell Transplantation, Histocompatibility, Humans, Immunosuppressive Agents, Kaplan-Meier Estimate, Male, Middle Aged, Neoplasm, Residual, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Retrospective Studies, Risk, Transplantation Conditioning, Young Adult
Abstract

Haploidentical transplantation performed with post-transplantation cyclophosphamide (PTCy)-based graft-versus-host disease (GVHD) prophylaxis has been associated with favorable outcomes for patients with acute myeloid leukemia and lymphomas. However, it remains unclear if such approach is effective for patients with acute lymphoblastic leukemia (ALL). We analyzed outcomes of 109 consecutively treated ALL patients 18 years of age and older at 5 institutions. The median age was 32 years and the median follow-up for survivors was 13 months. Thirty-two patients were in first complete remission (CR1), while the rest were beyond CR1. Neutrophil engraftment occurred in 95% of the patients. The cumulative incidences of grades II to IV and III and IV acute GVHD at day 100 after transplantation were 32% and 11%, respectively, whereas chronic GVHD, nonrelapse mortality, relapse rate, and disease-free survival (DFS) at 1 year after transplantation were 32%, 21%, 27%, and 51%, respectively. Patients in CR1 had 52% DFS at 3 years. These results suggest that haploidentical transplants performed with PTCy-based GVHD prophylaxis provide a very suitable alternative to HLA-matched transplantations for patients with ALL.

Published
2017

11. Chronic lymphocytic leukemia/small lymphocytic lymphoma, version 1.2015.

Author

Zelenetz, Andrew D, Gordon, Leo I, Wierda, William G, Abramson, Jeremy S, Advani, Ranjana H, Andreadis, C Babis, Bartlett, Nancy, Byrd, John C, Czuczman, Myron S, Fayad, Luis E, Fisher, Richard I, Glenn, Martha J, Habermann, Thomas M, Harris, Nancy Lee, Hoppe, Richard T, Horwitz, Steven M, Kelsey, Christopher R, Kim, Youn H, Krivacic, Susan, LaCasce, Ann S, Nademanee, Auayporn, Porcu, Pierluigi, Press, Oliver, Rabinovitch, Rachel, Reddy, Nishitha, Reid, Erin, Saad, Ayman A, Sokol, Lubomir, Swinnen, Lode J, Tsien, Christina, Vose, Julie M, Wilson, Lynn, Yahalom, Joachim, Zafar, Nadeem, Dwyer, Mary, and Sundar, Hema

Subjects
Biomedical and Clinical Sciences, Cardiovascular Medicine and Haematology, Oncology and Carcinogenesis, Orphan Drug, Hematology, Clinical Research, Rare Diseases, Lymphoma, Cancer, Algorithms, Comorbidity, Disease Management, Humans, Leukemia, Lymphocytic, Chronic, B-Cell, Neoplasm Staging, Prognosis, National comprehension cancer network, Oncology & Carcinogenesis, Oncology and carcinogenesis, Health services and systems
Abstract

Chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) are different manifestations of the same disease, which are managed in the same way. The advent of novel monoclonal antibodies (ofatumumab and obinutuzumab) led to the development of effective chemoimmunotherapy regimens. The recently approved small molecule kinase inhibitors (ibrutinib and idelalisib) are effective treatment options for CLL in elderly patients with decreased tolerance for aggressive regimens and in patients with poor prognostic features who do not benefit from conventional chemoimmunotherapy regimens. This portion of the NCCN Guidelines for Non-Hodgkin's Lymphomas describes the recent specific to the incorporation of recently approved targeted therapies for the management of patients with newly diagnosed and relapsed or refractory CLL/SLL.

Published
2015

12. Non-Hodgkin's lymphomas, version 4.2014.

Author

Zelenetz, Andrew D, Gordon, Leo I, Wierda, William G, Abramson, Jeremy S, Advani, Ranjana H, Andreadis, C Babis, Bartlett, Nancy, Byrd, John C, Czuczman, Myron S, Fayad, Luis E, Fisher, Richard I, Glenn, Martha J, Harris, Nancy Lee, Hoppe, Richard T, Horwitz, Steven M, Kelsey, Christopher R, Kim, Youn H, Krivacic, Susan, LaCasce, Ann S, Nademanee, Auayporn, Porcu, Pierluigi, Press, Oliver, Rabinovitch, Rachel, Reddy, Nishitha, Reid, Erin, Saad, Ayman A, Sokol, Lubomir, Swinnen, Lode J, Tsien, Christina, Vose, Julie M, Yahalom, Joachim, Zafar, Nadeem, Dwyer, Mary, and Sundar, Hema

Subjects
Biomedical and Clinical Sciences, Cardiovascular Medicine and Haematology, Oncology and Carcinogenesis, Cancer, Hematology, Rare Diseases, Stem Cell Research, Lymphoma, Clinical Research, 6.1 Pharmaceuticals, Evaluation of treatments and therapeutic interventions, 6.2 Cellular and gene therapies, Humans, Lymphoma, Non-Hodgkin, Neoplasm Staging, Recurrence, National comprehensive cancer network, Oncology & Carcinogenesis, Oncology and carcinogenesis, Health services and systems
Abstract

Non-Hodgkin's lymphomas (NHL) are a heterogeneous group of lymphoproliferative disorders originating in B lymphocytes, T lymphocytes, or natural killer cells. Mantle cell lymphoma (MCL) accounts for approximately 6% of all newly diagnosed NHL cases. Radiation therapy with or without systemic therapy is a reasonable approach for the few patients who present with early-stage disease. Rituximab-based chemoimmunotherapy followed by high-dose therapy and autologous stem cell rescue (HDT/ASCR) is recommended for patients presenting with advanced-stage disease. Induction therapy followed by rituximab maintenance may provide extended disease control for those who are not candidates for HDT/ASCR. Ibrutinib, a Bruton tyrosine kinase inhibitor, was recently approved for the treatment of relapsed or refractory disease. This manuscript discusses the recommendations outlined in the NCCN Guidelines for NHL regarding the diagnosis and management of patients with MCL.

Published
2014

14. Melphalan-Based Reduced-Intensity Conditioning is Associated with Favorable Disease Control and Acceptable Toxicities in Patients Older Than 70 with Hematologic Malignancies Undergoing Allogeneic Hematopoietic Stem Cell Transplantation

Author

Al Malki, Monzr M., Nathwani, Nitya, Yang, Dongyun, Armenian, Saro, Dadwal, Sanjeet, Salman, Jaroslava, Mokhtari, Sally, Cao, Thai, Sandhu, Karamjeet, Rouse, Michelle, Mei, Matthew, Ali, Haris, Parker, Pablo, Alvarnas, Joseph, Smith, Eileen, Donnell, Margaret O., Marcucci, Guido, Snyder, David, Nademanee, Auayporn, Forman, Stephen J., Stein, Anthony, and Nakamura, Ryotaro

Published
2018
Full Text
View/download PDF

16. Outcomes after Allogeneic Stem Cell Transplantation in Patients with Double-Hit and Double-Expressor Lymphoma

Author

Herrera, Alex F., Rodig, Scott J., Song, Joo Y., Kim, Young, Griffin, Gabriel K., Yang, Dongyun, Nikolaenko, Liana, Mei, Matthew, Bedell, Victoria, Dal Cin, Paola, Pak, Christine, Alyea, Edwin P., Budde, Lihua E., Chen, Robert, Chen, Yi-Bin, Chan, Wing C., Cutler, Corey S., Ho, Vincent T., Koreth, John, Krishnan, Amrita, Murata-Collins, Joyce L., Nikiforow, Sarah, Palmer, Joycelynne, Pihan, German A., Pillai, Raju, Popplewell, Leslie, Rosen, Steven T., Siddiqi, Tanya, Sohani, Aliyah R., Zain, Jasmine, Kwak, Larry W., Weisenburger, Dennis D., Weinstock, David M., Soiffer, Robert J., Antin, Joseph H., Forman, Stephen J., Nademanee, Auayporn P., and Armand, Philippe

Published
2018
Full Text
View/download PDF

17. Clinical Practice Recommendations on Indication and Timing of Hematopoietic Cell Transplantation in Mature T Cell and NK/T Cell Lymphomas: An International Collaborative Effort on Behalf of the Guidelines Committee of the American Society for Blood and Marrow Transplantation

Author

Kharfan-Dabaja, Mohamed A., Kumar, Ambuj, Ayala, Ernesto, Hamadani, Mehdi, Reimer, Peter, Gisselbrecht, Christian, d'Amore, Francesco, Jantunen, Esa, Ishida, Takashi, Bazarbachi, Ali, Foss, Francine, Advani, Ranjana, Fenske, Timothy S., Lazarus, Hillard M., Friedberg, Jonathan W., Aljurf, Mahmoud, Sokol, Lubomir, Tobinai, Kensei, Tse, Eric, Burns, Linda J., Chavez, Julio C., Reddy, Nishitha M., Suzuki, Ritsuro, Ahmed, Sairah, Nademanee, Auayporn, Mohty, Mohamad, Gopal, Ajay K., Fanale, Michelle A., Pro, Barbara, Moskowitz, Alison J., Sureda, Anna, Perales, Miguel Angel, Carpenter, Paul A., and Savani, Bipin N.

Published
2017
Full Text
View/download PDF

18. Long-Term Results of High-Dose Therapy and Autologous Stem Cell Transplantation for Mantle Cell Lymphoma: Effectiveness of Maintenance Rituximab

Author

Mei, Matthew G., Cao, Thai M., Chen, Lu, Song, Joo Y., Siddiqi, Tanya, Cai, Ji-Lian, Farol, Leonardo T., Al Malki, Monzr M., Salhotra, Amandeep, Aldoss, Ibrahim, Palmer, Joycelynne, Herrera, Alex F., Zain, Jasmine, Popplewell, Leslie L., Chen, Robert W., Rosen, Steven T., Forman, Stephen J., Kwak, Larry, Nademanee, Auayporn P., and Budde, Lihua E.

Published
2017
Full Text
View/download PDF

19. Results of a Phase 2 Trial of Allogeneic Hematopoietic Stem Cell Transplantation using 90Y-Ibritumomab Tiuxetan (Zevalin®) in Combination with Fludarabine and Melphalan in Patients with High-Risk B-Cell Non-Hodgkin's Lymphoma

Author

Mei, Matthew, primary, Palmer, Joycelynne, additional, Tsai, Nicole Ni-Chun, additional, Simpson, Jennifer, additional, O'Hearn, James, additional, Stein, Anthony, additional, Forman, Stephen, additional, Spielberger, Ricardo, additional, Cai, Ji-Lian, additional, Htut, Myo, additional, Nakamura, Ryotaro, additional, Malki, Monzr M Al, additional, Herrera, Alex, additional, Wong, Jeffrey, additional, and Nademanee, Auayporn, additional

Published
2023
Full Text
View/download PDF

23. CD25 Blockade Delays Regulatory T Cell Reconstitution and Does Not Prevent Graft-versus-Host Disease After Allogeneic Hematopoietic Cell Transplantation

Author

Locke, Frederick L., Pidala, Joseph, Storer, Barry, Martin, Paul J., Pulsipher, Michael A., Chauncey, Thomas R., Jacobsen, Niels, Kröger, Nicolaus, Walker, Irwin, Light, Susan, Shaw, Bronwen E., Beato, Francisca, Laport, Ginna G., Nademanee, Auayporn, Keating, Armand, Socie, Gerard, and Anasetti, Claudio

Published
2017
Full Text
View/download PDF

27. Supplementary Data from Double-hit Signature with TP53 Abnormalities Predicts Poor Survival in Patients with Germinal Center Type Diffuse Large B-cell Lymphoma Treated with R-CHOP

Author

Song, Joo Y., primary, Perry, Anamarija M., primary, Herrera, Alex F., primary, Chen, Lu, primary, Skrabek, Pamela, primary, Nasr, Michel R., primary, Ottesen, Rebecca A., primary, Nikowitz, Janet, primary, Bedell, Victoria, primary, Murata-Collins, Joyce, primary, Li, Yuping, primary, McCarthy, Christine, primary, Pillai, Raju, primary, Wang, Jinhui, primary, Wu, Xiwei, primary, Zain, Jasmine, primary, Popplewell, Leslie, primary, Kwak, Larry W., primary, Nademanee, Auayporn P., primary, Niland, Joyce C., primary, Scott, David W., primary, Gong, Qiang, primary, Chan, Wing C., primary, and Weisenburger, Dennis D., primary

Published
2023
Full Text
View/download PDF

28. Reduced-Intensity Conditioning with Fludarabine, Cyclophosphamide, and High-Dose Rituximab for Allogeneic Hematopoietic Cell Transplantation for Follicular Lymphoma: A Phase Two Multicenter Trial from the Blood and Marrow Transplant Clinical Trials Network

Author

Laport, Ginna G., Wu, Juan, Logan, Brent, Bachanova, Veronika, Hosing, Chitra, Fenske, Timothy, Longo, Walter, Devine, Steven M., Nademanee, Auayporn, Gersten, Iris, Horowitz, Mary, Lazarus, Hillard M., and Riches, Marcie L.

Published
2016
Full Text
View/download PDF

30. Results of a Phase II Trial of Allogeneic Hematopoietic Stem Cell Transplantation Using 90Y-Ibritumomab Tiuxetan (Zevalin) in Combination With Fludarabine and Melphalan in Patients With High-Risk B-Cell Non-Hodgkin's Lymphoma.

Author

Mei, Matthew, Palmer, Joycelynne, Ni-Chun Tsai, Nicole, Simpson, Jennifer, O'Hearn, James, Stein, Anthony, Forman, Stephen, Spielberger, Ricardo, Cai, Ji-Lian, Htut, Myo, Nakamura, Ryotaro, Malki, Monzr M. Al, Herrera, Alex, Wong, Jeffrey, and Nademanee, Auayporn

Published
2023
Full Text
View/download PDF

31. Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin's lymphoma at risk of relapse or progression (AETHERA): a randomised, double-blind, placebo-controlled, phase 3 trial

Author

Moskowitz, Craig H, Nademanee, Auayporn, Masszi, Tamas, Agura, Edward, Holowiecki, Jerzy, Abidi, Muneer H, Chen, Andy I, Stiff, Patrick, Gianni, Alessandro M, Carella, Angelo, Osmanov, Dzhelil, Bachanova, Veronika, Sweetenham, John, Sureda, Anna, Huebner, Dirk, Sievers, Eric L, Chi, Andy, Larsen, Emily K, Hunder, Naomi N, and Walewski, Jan

Published
2015
Full Text
View/download PDF

33. An enhanced International Prognostic Index (NCCN-IPI) for patients with diffuse large B-cell lymphoma treated in the rituximab era

Author

Zhou, Zheng, Sehn, Laurie H., Rademaker, Alfred W., Gordon, Leo I., LaCasce, Ann S., Crosby-Thompson, Allison, Vanderplas, Ann, Zelenetz, Andrew D., Abel, Gregory A., Rodriguez, Maria A., Nademanee, Auayporn, Kaminski, Mark S., Czuczman, Myron S., Millenson, Michael, Niland, Joyce, Gascoyne, Randy D., Connors, Joseph M., Friedberg, Jonathan W., and Winter, Jane N.

Published
2014
Full Text
View/download PDF

34. Multi-center phase II trial of bortezomib and rituximab maintenance combination therapy in patients with mantle cell lymphoma after consolidative autologous stem cell transplantation

Author

Chen, Robert W., Palmer, Joycelynne M., Tomassetti, Sarah, Popplewell, Leslie L., Alluin, Jessica, Chomchan, Pritsana, Nademanee, Auayporn P., Siddiqi, Tanya, Tsai, Ni-Chun, Chen, Lu, Zuo, Fay, Abary, Rosemarie, Cai, Ji-lian, Herrera, Alex F., Rossi, John J., Rosen, Steven T., Forman, Stephen J., Kwak, Larry W., and Holmberg, Leona A.

Published
2018
Full Text
View/download PDF

35. Plerixafor Plus Granulocyte Colony-Stimulating Factor versus Placebo Plus Granulocyte Colony-Stimulating Factor for Mobilization of CD34+ Hematopoietic Stem Cells in Patients with Multiple Myeloma and Low Peripheral Blood CD34+ Cell Count: Results of a Subset Analysis of a Randomized Trial

Author

Nademanee, Auayporn P., DiPersio, John F., Maziarz, Richard T., Stadtmauer, Edward A., Micallef, Ivana N., Stiff, Patrick J., Hsu, Frank J., Bridger, Gary, and Bolwell, Brian J.

Published
2012
Full Text
View/download PDF

44. Clinical and Ultrasonic Evaluation of Spleen Size during Peripheral Blood Progenitor Cell Mobilization by Filgrastim: Results of an Open-Label Trial in Normal Donors

Author

Stiff, Patrick J., Bensinger, William, Abidi, Muneer H., Gingrich, Roger, Artz, Andrew S., Nademanee, Auayporn, Hansen, Keith S., Sobczak, Christopher, Cutler, Corey, Bolwell, Brian, Shore, Tsiporah B., Lazarus, Hillard M., Yeager, Andrew M., Lovelace, Wade, Guo, Matthew, and Dreiling, Lyndah

Published
2009
Full Text
View/download PDF

49. Double-hit Signature with TP53 Abnormalities Predicts Poor Survival in Patients with Germinal Center Type Diffuse Large B-cell Lymphoma Treated with R-CHOP

Author

Song, Joo Y., primary, Perry, Anamarija M., additional, Herrera, Alex F., additional, Chen, Lu, additional, Skrabek, Pamela, additional, Nasr, Michel R., additional, Ottesen, Rebecca A., additional, Nikowitz, Janet, additional, Bedell, Victoria, additional, Murata-Collins, Joyce, additional, Li, Yuping, additional, McCarthy, Christine, additional, Pillai, Raju, additional, Wang, Jinhui, additional, Wu, Xiwei, additional, Zain, Jasmine, additional, Popplewell, Leslie, additional, Kwak, Larry W., additional, Nademanee, Auayporn P., additional, Niland, Joyce C., additional, Scott, David W., additional, Gong, Qiang, additional, Chan, Wing C., additional, and Weisenburger, Dennis D., additional

Published
2021
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results